Veera K. Ojala

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

DMPA is a de novo multi-omics method that discovers signaling pathways and regulatory relationships across omics data, outperforming existing methods in low-sample and zero-inflated datasets.